Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EPS (Weighted Average and Diluted) (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.69 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 89.06% year-over-year to -$0.69; the TTM value through Sep 2025 reached -$2.9, up 81.4%, while the annual FY2024 figure was -$12.03, 36.01% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.69 in Q3 2025 per SNTI's latest filing, down from -$0.18 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.81 in Q3 2022 and bottomed at -$8.26 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$2.16, with a median of -$1.14 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 120.88% in 2022, then tumbled 4744.44% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$3.67 in 2021, then skyrocketed by 102.45% to $0.09 in 2022, then crashed by 4744.44% to -$4.18 in 2023, then soared by 85.17% to -$0.62 in 2024, then dropped by 11.29% to -$0.69 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.69 in Q3 2025, -$0.18 in Q2 2025, and -$1.41 in Q1 2025.